

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM311840

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
TRIMEL BIOPHARMA SRL		07/16/2014	COMPANY:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	MIDCAP FUNDING V, LLC		
<b>Street Address:</b>	7255 WOODMONT AVENUE		
<b>Internal Address:</b>	SUITE 200		
<b>City:</b>	BETHESDA		
<b>State/Country:</b>	MARYLAND		
<b>Postal Code:</b>	20814		
<b>Entity Type:</b>	LIMITED LIABILITY COMPANY: DELAWARE		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	77932590	COMPLEO TRT	
<b>Serial Number:</b>	85230489	TRI AIR DEPOSITION SYSTEM	
<b>Serial Number:</b>	85527122	TEFINA	
<b>Serial Number:</b>	86084664	NATESTO	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7037125050		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	703-712-5315		
<b>Email:</b>	bsisson@mcguirewoods.com		
<b>Correspondent Name:</b>	Bradley Sisson		
<b>Address Line 1:</b>	1750 Tysons Blvd		
<b>Address Line 2:</b>	Suite 1800		
<b>Address Line 4:</b>	Tysons Corner, VIRGINIA 22102		
<b>ATTORNEY DOCKET NUMBER:</b>	2061695-0037		
<b>NAME OF SUBMITTER:</b>	Bradley Sisson		
<b>SIGNATURE:</b>	/Bradley Sisson/		
<b>DATE SIGNED:</b>	07/24/2014		
<b>Total Attachments: 15</b>			

OP \$115.00 77932590

source=MidcapTrimelSecurityAgreementFiling#page1.tif  
source=MidcapTrimelSecurityAgreementFiling#page2.tif  
source=MidcapTrimelSecurityAgreementFiling#page3.tif  
source=MidcapTrimelSecurityAgreementFiling#page4.tif  
source=MidcapTrimelSecurityAgreementFiling#page5.tif  
source=MidcapTrimelSecurityAgreementFiling#page6.tif  
source=MidcapTrimelSecurityAgreementFiling#page7.tif  
source=MidcapTrimelSecurityAgreementFiling#page8.tif  
source=MidcapTrimelSecurityAgreementFiling#page9.tif  
source=MidcapTrimelSecurityAgreementFiling#page10.tif  
source=MidcapTrimelSecurityAgreementFiling#page11.tif  
source=MidcapTrimelSecurityAgreementFiling#page12.tif  
source=MidcapTrimelSecurityAgreementFiling#page13.tif  
source=MidcapTrimelSecurityAgreementFiling#page14.tif  
source=MidcapTrimelSecurityAgreementFiling#page15.tif

**U.S. INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This U.S. Intellectual Property Security Agreement is entered into as of the 16th day of July, 2014 by and among **MIDCAP FUNDING V, LLC**, a Delaware limited liability company (“**Agent**”), and **TRIMEL BIOPHARMA SRL**, a society with restricted liability established under the *Companies Act* of the laws of Barbados (“**Grantor**”).

RECITALS

A. The Lenders (as defined below) have agreed to make certain advances of money and to extend certain financial accommodation (the “**Credit Extensions**”) to Trimel Pharmaceuticals Corporation, a corporation formed under the laws of the Province of Ontario (the “**Borrower**”) in the amounts and manner set forth in that certain Credit and Security Agreement by and among Agent, the financial institutions party thereto from time to time (collectively, the “**Lenders**”), Borrower, and Trimel BioPharma Holdings Inc., a company incorporated under the Companies Act of the laws of Barbados (“**TBH**”), together with Grantor as Credit Parties thereto, dated as the date hereof (as the same may be amended, modified or supplemented from time to time, the “**Credit Agreement**”; capitalized terms used herein are used as defined in the Credit Agreement).

B. Grantor has executed that certain Guaranty Agreement dated as of July 16, 2014 (the “**Guaranty**”) in favor of Agent (for the benefit of the Lenders) with respect to the obligations of Borrower under the Credit Agreement.

C. The Lenders are willing to make the Credit Extensions to Borrower, but only upon the condition, among others, that Grantor execute this Agreement to secure the obligations owing by Grantor to Agent and Lenders under (i) the Credit Agreement (the “**Credit Agreement Obligations**”) and (ii) the Guaranty (the “**Guaranteed Obligations**”, together with the Credit Agreement Obligations, the “**Obligations**”) and grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the Obligations.

D. Pursuant to the terms of the Credit Agreement and Guaranty, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (as specifically defined in the Credit Agreement).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its Obligations, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its Obligations, Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or

held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

For the avoidance of any doubt, the Intellectual Property Collateral shall include, and Agent shall have a Lien and security interest in, (i) all IP Proceeds, and (ii) all payments with respect to IP Proceeds that are received after the commencement of a bankruptcy or insolvency proceeding. The term “IP Proceeds” means, collectively, all cash, Accounts, license and royalty fees, claims, products, awards, judgments, insurance claims, and other revenues, proceeds or income, arising out of, derived from or relating to any Intellectual Property Collateral of Grantor, and any claims for damage by way of any past, present or future infringement of any Intellectual Property Collateral of Grantor (including, without limitation, all cash, royalty fees, other proceeds, Accounts and General Intangibles that consist of rights of payment to or on behalf of Grantor and the proceeds from the sale, licensing or other disposition of all or any part of, or rights in, any Intellectual Property Collateral by or on behalf of Grantor).

This security interest is granted in conjunction with the security interests granted to Agent, for the ratable benefit of the Lenders, under the Credit Agreement, Guaranty and certain other security documents and instruments executed in connection therewith. The rights and remedies of Agent with

respect to the security interests granted hereby are in addition to those set forth in the Credit Agreement, Guaranty and the other Financing Documents, security documents and instruments, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Credit Agreement, Guaranty or any of the Financing Documents, security documents or instruments, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Credit Agreement, Guaranty or any of the other Financing Documents, security documents or instruments, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.


*[Remainder of page intentionally blank; signature page follows.]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:  
Suite B, Durants Business Centre  
Durants, Christ Church, Barbados, BB17097  
Attn: \_\_\_\_\_

GRANTOR:

TRIMEL BIOPHARMA SRL

By:   
Name: HUBERT T. CZERWINSKI  
Title: PRESIDENT

INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

TRADEMARK  
REEL: 005329 FRAME: 0597

AGENT:

Address of Agent:

MIDCAP FUNDING V, LLC

7255 Woodmont Avenue, Suite 200  
Bethesda, Maryland 20814  
Attn: Portfolio Management- Life Sciences


By:   
Name: William Gould  
Title: Authorized Signatory

EXHIBIT A

Copyrights

Nil



EXHIBIT B

U.S. Patents and Patent Applications

*Bioadhesive Nasal Gel Related Owned Patent Applications*

Borrower that is Owner of IP	Country Name	Name / Identifier of IP	Type of IP (e.g., patent, TM, ©, mask work)	Registration/Publication or Application Number	Filing Date
Trimel BioPharma SRL	United States of America	INTRANASAL 0.6% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/513,497	29-Jul-11
	United States of America	INTRANASAL 0.6% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/486,251	14-May-11
	United States of America	INTRANASAL 0.6% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/518,921	13-May-11
	United States of America	INTRANASAL 0.6% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/598,329	13-Feb-12
	United States of America	INTRANASAL 0.6% AND 0.72% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	13/471,445	14-May-12
	United States of America	INTRANASAL 0.45% AND 0.48% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	13/471,449	14-May-12
	United States of America	INTRANASAL 0.45% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/598,333	13-Feb-12
	United States of America	INTRANASAL 0.45% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/486,252	14-May-11
	United States of America	INTRANASAL 0.45% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/518,916	13-May-11
	United States of America	INTRANASAL 0.45% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/513,495	29-Jul-11
	United States of America	INTRANASAL 0.15% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/513,499	29-Jul-11
	United States of America	INTRANASAL 0.15% AND 0.24% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	13/471,450	14-May-12
	United States of America	INTRANASAL 0.15% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/518,903	13-May-11
	United States of	INTRANASAL 0.15% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR	Patent Application	61/486,254	14-May-11

America	TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER			
United States of America	INTRANASAL 0.15% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/598,335	13-Feb-12
United States of America	INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/486,266	14-May-11
United States of America	INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/518,913	13-May-11
United States of America	INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/598,336	13-Feb-12
United States of America	INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	13/471,452	14-May-12
United States of America	INTRANASAL TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING MALE HYPOGONADISM	Patent Application	61/486,324	15-May-11
United States of America	INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING MALE HYPOGONADISM	Patent Application	61/486,634	16-May-11
United States of America	INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING MALE HYPOGONADISM	Patent Application	14/082,032	15-Nov-13
United States of America	MALE TESTOSTERONE TITRATION METHODS, MALE INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING HYPOGONADISM AND TRT	Patent Application	61/729,138	21-Nov-12
United States of America	MALE TESTOSTERONE TITRATION METHODS, MALE INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING HYPOGONADISM AND TRT	Patent Application	61/729,406	22-Nov-12
United States of America	CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS	Patent Application	14/080,695	14-Nov-13
United States of America	CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS	Patent Application	61/729,304	21-Nov-12
United States of America	CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS	Patent Application	61/726,564	14-Nov-12
United States of America	CONTROLLED RELEASE NASAL TESTOSTERONE GELS, METHODS AND PRE-FILLED MULTI-DOSE APPLICATOR SYSTEMS FOR PERNASAL ADMINISTRATION	Patent Application	14/081,751	15-Nov-13
United States of America	FEMALE INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/729,324	21-Nov-12
United States of America	FEMALE INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/727,112	15-Nov-12
United States of America	FEMALE INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/726,570	14-Nov-12

States of America	STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Application		
United States of America	FEMALE INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	14/080,732	14-Nov-13
United States of America	PRIMARY AND SECONDARY EFFICACY AND SAFETY ENDPOINTS FOR CONTROLLED RELEASE TOPICAL TESTOSTERONE GEL FORMULATIONS AND METHODS	Patent Application	61/802,739	17-Mar-13
United States of America	PRIMARY AND SECONDARY EFFICACY AND SAFETY ENDPOINTS FOR CONTROLLED RELEASE TOPICAL TESTOSTERONE GEL FORMULATIONS AND METHODS	Patent Application	61/802,737	17-Mar-13
United States of America	PRIMARY AND SECONDARY EFFICACY AND SAFETY ENDPOINTS FOR CONTROLLED RELEASE TOPICAL TESTOSTERONE GEL FORMULATIONS AND METHODS	Patent Application	61/802,388	16-Mar-13
United States of America	ONE- AND TWO-POINT TITRATION METHODS TO DETERMINE DAILY TREATMENT REGIMENS TO TREAT HYPOGONADISM OR MALE TESTOSTERONE DEFICIENCY WITH AN INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL	Patent Application	61/802,354	15-Mar-13
United States of America	ONE-AND TWO-POINT TITRATION METHODS TO DETERMINE DAILY TREATMENT REGIMENS TO TREAT HYPOGONADISM OR MALE TESTOSTERONE DEFICIENCY WITH AN INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL	Patent Application	61/802,724	17-Mar-13
United States of America	ONE- AND TWO-POINT TITRATION METHODS TO DETERMINE DAILY TREATMENT REGIMENS TO TREAT HYPOGONADISM OR MALE TESTOSTERONE DEFICIENCY WITH AN INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL	Patent Application	61/802,727	17-Mar-13
United States of America	METHODS OF TREATING HYPOGONADISM WITH TRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS IN MALE WITH ALLERGIC RHINITIS, AND METHODS FOR PREVENTING AN ALLERGIC RHINITIS EVENTS	Patent Application	61/802,297	15-Mar-13

*Bioadhesive Nasal Gel Related Licensed Patents and Patent Applications*

*TriVair Related Owned Patents and Patent Applications*

Borrower that is Owner of IP	Country Name	Name / Identifier of IP	Type of IP (e.g., patent, TM, ©, mask work)	Expiration Date
TBS	US	5797392	Owned Patent	22.01.2016
TBS	US	6811543	Owned Patent	26.05.2018
TBS	US	7661425	Owned Patent	30.06.2026
TBS	US	6648848	Owned Patent	26.05.2018

EXHIBIT C

Trademarks

Title	Country	Appl'n No.	Serial No.	Filing Date	Applicant	Status	Next Renewal Date	Comments
COMPLEO TRT	Australia	1345400	1345400	Feb 12, 2010	Trimel Biopharma SRL	Registered Feb 12, 2010.	Renewal due Feb 11, 2020.	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	Canada	1427288	1427288	Jan 30, 2009	Trimel Biopharma SRL	Allowed Feb 25, 2011.	File decl'n of use by July 30, 2014.	
COMPLEO TRT	China	8129778	8129778	Feb 24, 2010	Trimel Biopharma SRL	Registered Mar 21, 2011.	Renewal due Mar 21, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	European Community	008876741	008876741	Feb 11, 2010	Trimel Biopharma SRL	Registered Feb 11, 2010.	Renewal due Feb 11, 2020.	Subject to cancellation if not used for any 5 consecutive years from Registration.
COMPLEO TRT	Hong Kong	301543905	301543905	Feb 11, 2010	Trimel Biopharma SRL	Registered Feb 11, 2010.	Renewal due February 10, 2020.	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	Japan	2010-009955	5456565	Feb 12, 2010	Trimel Biopharma SRL	Registered Dec 9, 2011.	Renewal December 9, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	New Zealand	819522	819522	Feb 11, 2010	Trimel Biopharma SRL	Registered Feb 11, 2010.	Feb 11, 2020	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	US	77932590	77932590	Feb 10, 2010	Trimel Biopharma SRL	Allowed Oct 11, 2011.	File stm't of use by <u>Oct 11, 2014</u>	
Direct-Haler	Denmark	VA 2000 01998	VR 2000 03451	May 8, 2000	Direct-Haler A/S	Registered July 19, 2000	Renewal due July 19, 2020	
Direct-Haler	European Community	001751684	001751684	July 12, 2000	Direct-Haler A/S	Registered Sept 13, 2001.	Renewal due July 31, 2020	

Title	Country	Appl'n No.	Serial No.	Filing Date	Applicant	Status	Next Renewal Date	Comments
Direct-Haler	India	1162704	1162704	Dec 30, 2002	Direct-Haler A/S	Registered March 23, 2007	Renewal due Dec 30, 2022	
Tri Air System & Design	Australia	1406483	1406483	Jan 31, 2011	Trimel Biopharma SRL	Registered Jan 31, 2011.	Renewal due Jan 31, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	Canada	1,493,393	1,493,393	Aug 6, 2010	Trimel Biopharma SRL	Allowed May 20, 2011.	File decl'n of use by Aug. 6, 2014. (extendible every 6 months until Aug 6, 2016)	
Tri Air System & Design	China	9109263	9109263	Jan 31, 2011	Trimel Biopharma SRL	Registered Feb 14, 2012.	Renewal due Feb 13, 2022.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	European Community	009698771	009698771	Jan 31, 2011	Trimel Biopharma SRL	Registered Jan 31, 2011.	Renewal due January 31, 2021.	Subject to cancellation if not used for any 5 consecutive years from Registration.
Tri Air System & Design	Hong Kong	301824877	301824877	Jan 31, 2011	Trimel Biopharma SRL	Registered Jan 31, 2011.	Renewal due May 30, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	Japan	2011-0058707	5411386	Jan 31, 2011	Trimel Biopharma SRL	Registered May 13, 2011.	Renewal due May 13, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	New Zealand	836534	836534	Jan 31, 2011	Trimel Biopharma SRL	Registered Aug 6, 2010.	Renewal due Aug 6, 2020.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	US	85230489	85230489	Jan 31, 2011	Trimel Biopharma SRL	Allowed Dec 27, 2011.	File stat'm't of use by June 27, 2014. (extendible every 6 months until Dec 27, 2014)	
TEFINA	Barbados	81/29089		Jan 23, 2012	Trimel Biopharma SRL	Pending		

Title	Country	Appl'n No.	Serial No.	Filing Date	Applicant	Status	Next Renewal Date	Comments
TEFINA	US	85527122		Jan 27, 2012	Trimel Biopharma SRL	Allowed Aug 14, 2012.	File stm't of use by Aug 14, 2014. (extendible every 6 months until Feb 14, 2016)	
TEFINA	Canada	1,562,563		Jan 30, 2012	Trimel Biopharma SRL	Allowed Mar 8, 2013	File Decl'n of use by Jan 30, 2015. (extendible every 6 months until Jan 30, 2018)	
TEFINA	Australia	1502450	1502450	July 12, 2012	Trimel Biopharma SRL	Registered Issued on November 19, 2012.	Renewal due July 12, 2022	Subject to cancellation if not used for any 3 consecutive years from Registration.
TEFINA	China	TBA	11211868	July 16, 2012	Trimel Biopharma SRL	Registered on December 7, 2013	Renewal due Dec 6, 2023	Subject to cancellation if not used for any 3 consecutive years from Registration.
TEFINA	European Community	011035268	011035268	July 12, 2012	Trimel Biopharma SRL	Registered Issued on December 18, 2012	Renewal due July 12, 2022	
TEFINA	Hong Kong	302313143	302313143	July 12, 2012	Trimel Biopharma SRL	Registered Issued on December 14, 2012	Renewal due July 11, 2022	Subject to cancellation if not used for any 3 consecutive years from Registration.
TEFINA	Japan	2012-56437	5533030	July 12, 2012	Trimel Biopharma SRL	Registered on November 2, 2012	Renewal due November 2, 2022	Subject to cancellation if not used for any 3 consecutive years from Registration.
TEFINA	New Zealand	962007	962007	July 12, 2012	Trimel Biopharma SRL	Registered	Renewal due Jan 23, 2022	Deemed Reg Date is January 23, 2012 Subject to cancellation if not used for any 3 consecutive years from Registration.
NATESTO	Barbados			Oct 2, 2013	Trimel Biopharma SRL	Pending		
NATESTO	United States	86/084,664		Oct. 7, 2013	Trimel Biopharma SRL	Pending		

Title	Country	App'l'n No.	Serial No.	Filing Date	Applicant	Status	Next Renewal Date	Comments
NATESTO	Canada	1,647,673		Oct. 8, 2013	Trimel Biopharma SRL	Pending		
NATESTO	Australia	1607228		Feb. 20, 2014	Trimel Biopharma SRL	Granted		
NATESTO	China			Mar. 3, 2014	Trimel Biopharma SRL	Pending		
NATESTO	European Community	012618931		Feb. 20, 2014	Trimel Biopharma SRL	Accepted; Opposition period expires June 28, 2014		
NATESTO	Hong Kong	992850		Feb. 20, 2014	Trimel Biopharma SRL	Application accepted June 20, 2014. Opposition period ends on September 19, 2014		
NATESTO	New Zealand	992850		Feb. 20, 2014	Trimel Biopharma SRL	Accepted; Opposition period expires June 28, 2014		
NATESTO	Japan	2014-13459		Feb. 24, 2014	Trimel Biopharma SRL	Pending		



EXHIBIT D

Mask Works

Nil